OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation MarketGlobal License Agreement • April 26th, 2021
• Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.
ContractGlobal License Agreement • December 4th, 2022
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
GLOBAL LICENSE AGREEMENT by and among PROTHENA BIOSCIENCES LIMITED and CELGENE SWITZERLAND LLC Dated as of May 24, 2024Global License Agreement • August 8th, 2024 • Prothena Corp Public LTD Co • Pharmaceutical preparations • New York
This GLOBAL LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of May 24, 2024 (the “Effective Date”) by and between Prothena Biosciences Limited, an Irish limited company (“Prothena”) and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene”). Celgene and Prothena are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
Global License Agreement for HBM9033 (MSLN-Targeted ADC)Global License Agreement • December 15th, 2023
Sign a Global License Agreement for OCH-NCNP1Global License Agreement • September 5th, 2019
EA Pharma Co., Ltd. (President, Yuji Matsue; Headquarters, Tokyo, Japan) (hereinafter “EA Pharma”) and National Center of Neurology and Psychiatry (President, Hidehiro Mizusawa; Headquarters, Tokyo, Japan) (hereinafter “NCNP”) have signed a worldwide exclusive license agreement for development, manufacture and marketing for all indications of OCH-NCNP1, which is under development by NCNP (hereinafter “OCH”).
UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseasesGlobal License Agreement • November 29th, 2021
• UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases
Global License Agreement in Hemophilia BGlobal License Agreement • June 24th, 2020
This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” "will,” “would” and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this presentation. These forward- looking statements include, but are not limited to, statements regarding the development of our gene therapies, the success of our collaborations, and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitatio
First TakeGlobal License Agreement • November 8th, 2022
Strategically moving pieces to align novel ophthalmology platform. We highlight that Ocuphire’s announced global license agreement for development and commercialization of its lead small molecule eye drop candidate Nyxol reflects one aspect of several positive strategic moves involving not only Ocuphire, but global healthcare company Viatris Inc. (VTRS; not rated), Famy Life Sciences (private), and Oyster Point Pharma (OYST; Buy; Caufield). At a high level, we note the announcement of Ocuphire’s exclusive development and commercialization license agreement with Famy directly coincides with Viatris’ announced acquisition of both: (1) Famy Life Sciences; and
GLOBAL LICENSEGlobal License Agreement • March 23rd, 2017 • England
This Pipedata Pro Global License Agreement ("Agreement") is made and entered into by and between: Zeataline Projects Limited ("Licensor") And:
GLOBAL LICENCE AGREEMENT SECURED FOR FLASH JOULE HEATING TECHNOLOGY WITH RICE UNIVERSITYGlobal License Agreement • May 31st, 2024
• MTM has secured the exclusive global rights to the patented Flash Joule Heating (FJH) technology for use in the recovery of Rare Earth Elements (REE), Critical Metals, and Metallic Compounds from Ores, Industrial Wastes, E-scrap, Batteries and a broad range of high intrinsic value raw materials, as developed by Dr. James Tour and his team at the prestigious Rice University in Houston, Texas.
ContractGlobal License Agreement • September 7th, 2020
Fingerprints and Sentry Enterprises partner to enable a first-of-its-kind Converged Biometric Credential for Physical and Logical Access
ContractGlobal License Agreement • December 23rd, 2019
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally- Acting Pan-Janus Kinase (JAK) Inhibitor Program
Pricol in deal with France’s BMS PowerSafe | 1Global License Agreement • January 31st, 2024
Coimbatore-based Pricol, a provider of automotive technology, has established an exclusive technical agreement with BMS PowerSafe, a subsidiary of the Startec Energy Group in France, to produce battery management systems (BMS) for all types of electric vehicles.
ALN-AT3 Global License TermsGlobal License Agreement • May 4th, 2018 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THESE ALN-AT3 GLOBAL LICENSE TERMS (this “Agreement”) are entered into as of January 6, 2018 (the “Execution Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Except where otherwise specifically provided herein, the rights and obligations set forth herein shall only become binding upon the Effective Date (which, when used in this Agreement, has the meaning provided in Amendment No. 2 (as defined herein)).
EPS CHINA DATA GLOBAL LICENSE AGREEMENTGlobal License Agreement • January 10th, 2019
IN CONSIDERATION OF the mutual promises set forth herein and attached hereto, Licensor and Licensee agree to be bound by the terms and conditions. AND THEREFORE IN WITNESS, Licensor and Licensee have caused this Agreement to be executed.
AMENDMENT TO GLOBAL LICENSE AGREEMENTGlobal License Agreement • March 25th, 2024 • Hall of Fame Resort & Entertainment Co • Services-miscellaneous amusement & recreation
THIS AMENDMENT TO GLOBAL LICENSE AGREEMENT (this “Amendment”) is made and entered into as of September 13, 2023, between NATIONAL FOOTBALL MUSEUM, INC., an Ohio non-profit corporation, doing business as Pro Football Hall of Fame (hereinafter “PFHOF”), and HOF VILLAGE NEWCO, LLC, a Delaware limited liability limited partnership (hereinafter “HOFV”), each a “Party” and collectively, the “Parties”.
GLOBAL LICENSE AGREEMENTGlobal License Agreement • April 14th, 2022 • Hall of Fame Resort & Entertainment Co • Services-miscellaneous amusement & recreation • Ohio
THIS GLOBAL LICENSE AGREEMENT (this “Agreement”) is made as of this 8th day of April 2022, which is also the date of the last signature hereto (the “Effective Date”), between NATIONAL FOOTBALL MUSEUM, INC., an Ohio non-profit corporation, doing business as Pro Football Hall of Fame (hereinafter “PFHOF”) and HOF Village Newco, LLC, a Delaware limited liability company (hereinafter “HOFV”), each a “Party” and collectively, the “Parties”.
AMENDED AND RESTATED GLOBAL LICENSE AGREEMENTGlobal License Agreement • September 17th, 2024 • Hall of Fame Resort & Entertainment Co • Services-miscellaneous amusement & recreation • Ohio
THIS AMENDED AND RESTATED GLOBAL LICENSE AGREEMENT (this “Agreement”) is made as of this 11th day of September 2024, which is also the date of the last signature hereto (the “Effective Date”), between NATIONAL FOOTBALL MUSEUM, INC., an Ohio non-profit corporation, doing business as Pro Football Hall of Fame (hereinafter “PFHOF”) and HOF VILLAGE NEWCO, LLC, a Delaware limited liability company (hereinafter “HOFV”), each a “Party” and collectively, the “Parties”, and amends, restates, replaces, and supersedes in its entirety that certain Global License Agreement between NATIONAL FOOTBALL MUSEUM, INC., an Ohio non-profit corporation, doing business as Pro Football Hall of Fame, and HOF VILLAGE NEWCO, LLC, a Delaware limited liability company, dated April 8, 2022 (“Original Global Agreement”).
